Aubert, R E <br/><br/>
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Aug 2010 
 - 716-21 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/j.1463-1326.2010.01225.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Diabetes Mellitus, Type 2--complications<br/>Female<br/>Fractures, Bone--chemically induced<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Incidence<br/>Male<br/>Middle Aged<br/>Pioglitazone<br/>Risk Factors<br/>Rosiglitazone<br/>Thiazolidinediones--adverse effects<br/>Treatment Outcome